Výsledky vyhledávání - "C. Boglione‐Kerrien"

Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient

Autor: Karim Boudjema, Marie-Clémence Verdier, C. Boglione‐Kerrien, M. Dermu, C. Jezequel, Florian Lemaitre, Eric Bellissant

Publikováno v: Transplant Infectious Disease
Transplant Infectious Disease, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩
Transplant Infectious Disease, Wiley, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩

International audience; Telaprevir is a novel NS3A/4A protease inhibitor approved in combination with ribavirin and peg-interferon alfa for the treatment of genotype-1 chronic hepatitis C. This drug is also known to be a potent cytochrome P450 3A and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014308669148c25f6450c3a924ed0e39
https://doi.org/10.1111/tid.12335

Zobrazit plný text záznamu

Plný text ve formátu HTML

Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose

Autor: S. Lalanne, Camille Tron, Florian Lemaitre, Eric Bellissant, Marie-Clémence Verdier, Antoine Petitcollin, S. Nimubona, C. Boglione-Kerrien

Publikováno v: Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩
Antimicrobial Agents and Chemotherapy, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩

Posaconazole is extensively used for prophylaxis for invasive fungal infections. The gastro-resistant tablet formulation has allowed the bioavailability issues encountered with the oral suspension to be overcome. However, overexposure is now frequent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c449e5cf0f7481ab985e29ac52732c5
https://doi.org/10.1128/aac.01166-17

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole

Autor: Cécile Vigneau, Camille Tron, Marie-Clémence Verdier, C. Boglione-Kerrien, R. Crochette, Florian Lemaitre, Antoine Petitcollin, Eric Bellissant

Publikováno v: Drug Metabolism and Pharmacokinetics
Drug Metabolism and Pharmacokinetics, 2016, 31 (5), pp.389-393. ⟨10.1016/j.dmpk.2016.05.001⟩
Drug Metabolism and Pharmacokinetics, Japanese Society for the Study of Xenobiotics, 2016, 31 (5), pp.389-393. ⟨10.1016/j.dmpk.2016.05.001⟩

International audience; Being a substrate of the cytochrome P450 3A4 (CYP3A4) isoenzyme, sirolimus metabolism is decreased when posaconazole is administered concomitantly. However, because of the poor bioavailability of the oral suspension of posacon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dbe015095ad4654329f28ef7d672ad3
https://pubmed.ncbi.nlm.nih.gov/27530708

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání